Literature DB >> 24482405

Profound reduction of ovarian estrogen by aromatase inhibition in obese women.

Lauren A Ross1, Alex J Polotsky, Alexander Kucherov, Andrew P Bradford, Jennifer Lesh, Justin Chosich, Nancy Gee, Nanette Santoro.   

Abstract

OBJECTIVE: It was hypothesized that aromatase inhibitor (AI)-induced interruption of estradiol negative feedback would modulate the reproductive hormone profile of obese women.
METHODS: Regularly cycling women aged 18-40 years with a BMI of 18-25 kg/m(2) (normal weight, n = 10) or >30 kg/m(2) (obese; n = 12) were given AI daily for 7 days. Urinary hormone profiles were compared between groups. Fourteen eumenorrheic, normal weight women not receiving AI stimulation served as historical controls. Urinary metabolites for LH, FSH, estradiol (E1c), and progesterone (Pdg) were measured and normalized to a 28-day cycle. Serum estrone and estradiol were measured in the late follicular phase.
RESULTS: Whole-cycle LH, FSH, and luteal Pdg excretion did not differ between obese (BMI = 37.1 + 7 kg/m(2) ) and normal weight women treated with AIs, although LH was greater in stimulated compared with unstimulated normal weight women. Whole cycle mean E1c was lower in AI-stimulated obese and normal weight participants compared with nonstimulated normal weight controls, but obese women treated with AI excreted far less E1c (467.7 ± 217.4 μg/mg Cr) than AI-treated normal weight women (911.4 ± 361.8 μg/mg Cr; P = 0.02). Follicular phase serum estrone and estradiol were also lower in AI-treated obese women versus AI-treated normal weight women (61.7 ± 22.8 and 18.3 ± 3.7 pg/ml versus 99.1 ± 30.5 and 37.7 ± 5.9 pg/ml, respectively; P = 0.034 and 0.005).
CONCLUSIONS: Normal gonadotropin output and luteal function occur at the expense of reduced E1c excretion in AI-treated women, and this discrepancy is particularly evident in obese women.
Copyright © 2014 The Obesity Society.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24482405      PMCID: PMC4037337          DOI: 10.1002/oby.20713

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  16 in total

1.  Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions.

Authors:  Yanira L Pagán; Serene S Srouji; Yarisie Jimenez; Anne Emerson; Sabrina Gill; Janet E Hall
Journal:  J Clin Endocrinol Metab       Date:  2006-01-24       Impact factor: 5.958

2.  The clinical relevance of luteal phase deficiency: a committee opinion.

Authors: 
Journal:  Fertil Steril       Date:  2012-07-20       Impact factor: 7.329

3.  Absolute bioavailability of letrozole in healthy postmenopausal women.

Authors:  A Sioufi; N Gauducheau; V Pineau; F Marfil; A Jaouen; J M Cardot; J Godbillon; C Czendlik; H Howald; C Pfister; F Vreeland
Journal:  Biopharm Drug Dispos       Date:  1997-12       Impact factor: 1.627

4.  Assessing menstrual cycles with urinary hormone assays.

Authors:  N Santoro; S L Crawford; J E Allsworth; E B Gold; G A Greendale; S Korenman; B L Lasley; D McConnell; P McGaffigan; R Midgely; M Schocken; M Sowers; G Weiss
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-11-19       Impact factor: 4.310

5.  Obesity affects spontaneous pregnancy chances in subfertile, ovulatory women.

Authors:  Jan Willem van der Steeg; Pieternel Steures; Marinus J C Eijkemans; J Dik F Habbema; Peter G A Hompes; Jan M Burggraaff; G Jur E Oosterhuis; Patrick M M Bossuyt; Fulco van der Veen; Ben W J Mol
Journal:  Hum Reprod       Date:  2007-12-11       Impact factor: 6.918

Review 6.  The pharmacology of letrozole.

Authors:  B P Haynes; M Dowsett; W R Miller; J M Dixon; A S Bhatnagar
Journal:  J Steroid Biochem Mol Biol       Date:  2003-10       Impact factor: 4.292

7.  Body size and ethnicity are associated with menstrual cycle alterations in women in the early menopausal transition: The Study of Women's Health across the Nation (SWAN) Daily Hormone Study.

Authors:  Nanette Santoro; Bill Lasley; Dan McConnell; Jenifer Allsworth; Sybil Crawford; Ellen B Gold; Joel S Finkelstein; Gail A Greendale; Jenny Kelsey; Stan Korenman; Judith L Luborsky; Karen Matthews; Rees Midgley; Lynda Powell; Janice Sabatine; Miriam Schocken; Mary Fran Sowers; Gerson Weiss
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

8.  Pulsatile luteinizing hormone amplitude and progesterone metabolite excretion are reduced in obese women.

Authors:  Akas Jain; Alex J Polotsky; Dana Rochester; Sarah L Berga; Tammy Loucks; Gohar Zeitlian; Karen Gibbs; Hanah N Polotsky; Sophia Feng; Barbara Isaac; Nanette Santoro
Journal:  J Clin Endocrinol Metab       Date:  2007-04-17       Impact factor: 5.958

9.  Characterization of reproductive hormonal dynamics in the perimenopause.

Authors:  N Santoro; J R Brown; T Adel; J H Skurnick
Journal:  J Clin Endocrinol Metab       Date:  1996-04       Impact factor: 5.958

10.  Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.

Authors:  Elizabeth J Folkerd; J Michael Dixon; Lorna Renshaw; Roger P A'Hern; Mitch Dowsett
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544

View more
  2 in total

1.  Morphine and kisspeptin influences on 5-α reductase and aromatase gene expression in adult male rats.

Authors:  Homayoun Khazali; Fariba Mahmoudi
Journal:  Iran J Basic Med Sci       Date:  2019-12       Impact factor: 2.699

2.  Aromatase Inhibition Ameliorates Decreased LH Output Found in Obese Women.

Authors:  Kelsey Jones; Sarah Ryan; Nichole E Carlson; Justin Chosich; Andrew P Bradford; Nanette Santoro; Alex J Polotsky
Journal:  Reprod Sci       Date:  2020-01-06       Impact factor: 3.060

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.